G207 Followed by Radiation Therapy in Malignant Glioma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00157703 |
Recruitment Status :
Completed
First Posted : September 12, 2005
Last Update Posted : December 16, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.
This study is a two stage phase 1 study, in which a de-escalating dosing scheme will be used, i.e. the first patients will receive the higher dose and if excessive toxicity occurs, the dose will be reduced for the following patients. The purpose of the dose de-escalation phase is to find the best safe dose of G207.
In the first stage of the study, treatment with G207 will be followed by focal radiation therapy on the following day, and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day.
All patients will return to the clinic 28 days and 3, 6, 9 and 12 months after G207 administration at which time clinical assessments will be performed, and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malignant Glioma | Drug: G207 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy |
Study Start Date : | May 2005 |
Actual Primary Completion Date : | October 2008 |
Actual Study Completion Date : | December 2008 |

- Drug: G207
1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
- Adverse events [ Time Frame: from 1st dose to end of study visit ]
- Radiographic response [ Time Frame: Withdrawal or death of last patient ]
- Performance scale [ Time Frame: Last patient out ]
- Overall survival [ Time Frame: Withdrawal or death of last patient ]
- Immune response [ Time Frame: Last patient out ]
- Presence of G207 in blood and saliva [ Time Frame: Last patient out ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologically proven residual/recurrent glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma which is progressive despite radiotherapy or chemotherapy
- Failed external beam radiotherapy > 5,000 CGy at least 4 weeks prior to enrollment
- Residual/recurrent lesion must be ≥ 1.0 cm and (for Stage 2 only) ≤ 4 cm in diameter as determined by magnetic resonance imaging (MRI)
-
Normal hematological, renal and liver function
- Absolute neutrophil count > 1500/mm3
- Platelets > 100,000/mm3
- Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.3 x control
- Creatinine < 1.7 mg/dl
- Total bilirubin < 1.5 mg/dl
- Transaminases < 4 times above the upper limits of the institutional norm
- Karnofsky Performance Status score ≥ 70
- Age > 19 years-old
- Capable of giving informed consent
- Must be willing to practice an effective barrier method of birth control for 2 months post G207 inoculation, whether male or female
- Females of childbearing potential: negative pregnancy test within 24 hours prior to G207 administration
Exclusion Criteria:
- Surgical resection within 4 weeks of enrolment
- Acute infection, granulocytopenia or medical condition precluding surgery
- Pregnant or lactating females
- History of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection
- Tumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatment or tumor involving both hemispheres or with subependymal/cerebral spinal fluid (CSF) dissemination
- Tumor position that could, in the Investigator's opinion, pose the risk of penetration of the cerebral ventricular system during inoculation with the study drug (Note: If penetration of the ventricular system is suspected or confirmed, G207 administration must be aborted.)
- Tumor locations that would expose the patient to unacceptable risk with radiation therapy
- Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpesvirus protocol)
- Prior participant in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment
- Required steroid increase within 2 weeks prior to injection
- HIV seropositive
- Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir)
- Active oral or genital herpes lesion
- Any contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc.
- Radiation treatment volume of greater than 4 cm maximum diameter (Stage 2 only)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00157703
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294-3410 |
Study Director: | Axel Mescheder, M.D. | Medigene AG |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Alice Chen, MediGene |
ClinicalTrials.gov Identifier: | NCT00157703 History of Changes |
Other Study ID Numbers: |
CT2001 |
First Posted: | September 12, 2005 Key Record Dates |
Last Update Posted: | December 16, 2008 |
Last Verified: | December 2008 |
Keywords provided by MediGene:
Malignant glioma Glioblastoma multiforme GBM Gliosarcoma Anaplastic astrocytoma |
Brain cancer Brain tumor Glioma recurrent/progressive malignant glioma |
Additional relevant MeSH terms:
Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |